Senior Vice President, Clinical Development
Hiring Company

The hiring company name is
confidential for this listing.
About the Role
Greater Boston, MA Area (Hybrid)
The Company is seeking an SVP (Head) of Clinical Development to lead a transatlantic team in the planning and management of all clinical assets, from Phase II through pivotal trials, NDA/BLA submission, and post-approval studies. The successful candidate will be responsible for the global clinical development activities of multiple clinical-stage assets, with a focus on hematology and a variety of other clinical indications. This role requires an MD with a minimum of 10 years' of industry clinical development experience, a proven track record in pivotal trials and regulatory filings, and prior direct line management experience. The ideal candidate will have a background in hematology, hematology-oncology, or immunology, and experience in presenting clinical strategy and data to executive leadership and the Board of Directors. Applicants for the SVP (Head) of Clinical Development position at the company should possess a high level of emotional intelligence, be highly collaborative, and demonstrate innovation in their approach. The role demands a leader with a low-ego, transparent, and authentic leadership style, who can thrive in a fast-paced, dynamic environment and is comfortable with ambiguity. While the company works with multiple modalities, experience in antibody development is a plus. The position is based in the Boston metro area and requires the flexibility to travel both in the US and globally as needed. The successful candidate will be part of a well-funded, public biotech with a multi-asset, late-stage pipeline, and will play a key role in the commercialization of transformative therapies across a range of related rare, ultra-rare, and mass-market disorders.
Functions:
- Medical Care/Hospital Administration
Est. Compensation
USD $150,000-$262,909 (total) per year
Estimated by Revelio Labs
About the Company
Well-funded, public biotech developing late-stage therapies across multiple modalities and indications
Industry
Biotechnology
Type
Public Company